258 related articles for article (PubMed ID: 15996721)
1. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
Eisses MJ; Velan T; Aldea GS; Chandler WL
Thromb Res; 2006; 117(6):689-703. PubMed ID: 15996721
[TBL] [Abstract][Full Text] [Related]
2. The kinetics of plasmin inhibition by aprotinin in vivo.
Kang HM; Kalnoski MH; Frederick M; Chandler WL
Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
[TBL] [Abstract][Full Text] [Related]
3. Reducing hemostatic activation during cardiopulmonary bypass: a combined approach.
Eisses MJ; Seidel K; Aldea GS; Chandler WL
Anesth Analg; 2004 May; 98(5):1208-16, table of contents. PubMed ID: 15105189
[TBL] [Abstract][Full Text] [Related]
4. Closed cardiopulmonary bypass circuits suppress thrombin generation during coronary artery bypass grafting.
Nakahira A; Sasaki Y; Hirai H; Fukui T; Matsuo M; Takahashi Y; Kotani S; Suehiro S
Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):555-60. PubMed ID: 20061337
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
6. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass.
Guzzetta NA; Bajaj T; Fazlollah T; Szlam F; Wilson E; Kaiser A; Tosone SR; Miller BE
Anesth Analg; 2008 Feb; 106(2):419-25, table of contents. PubMed ID: 18227295
[TBL] [Abstract][Full Text] [Related]
7. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass.
Chandler WL
J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):459-67. PubMed ID: 16085250
[TBL] [Abstract][Full Text] [Related]
8. Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children.
Eisses MJ; Chandler WL
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):53-9. PubMed ID: 18249331
[TBL] [Abstract][Full Text] [Related]
9. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
Koster A; Fischer T; Gruendel M; Mappes A; Kuebler WM; Bauer M; Kuppe H
J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):171-5. PubMed ID: 12698397
[TBL] [Abstract][Full Text] [Related]
10. Changes in hemostasis during pediatric heart surgery: impact of a biocompatible heparin-coated perfusion system.
Jensen E; Andréasson S; Bengtsson A; Berggren H; Ekroth R; Larsson LE; Ouchterlony J
Ann Thorac Surg; 2004 Mar; 77(3):962-7. PubMed ID: 14992907
[TBL] [Abstract][Full Text] [Related]
11. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations.
Dietrich W; Mössinger H; Spannagl M; Jochum M; Wendt P; Barankay A; Meisner H; Richter JA
J Thorac Cardiovasc Surg; 1993 Apr; 105(4):712-20. PubMed ID: 7682267
[TBL] [Abstract][Full Text] [Related]
12. Activation of the hemostatic system during cardiopulmonary bypass.
Sniecinski RM; Chandler WL
Anesth Analg; 2011 Dec; 113(6):1319-33. PubMed ID: 22003219
[TBL] [Abstract][Full Text] [Related]
13. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
[TBL] [Abstract][Full Text] [Related]
14. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass.
Noguchi M; Eishi K; Tada S; Yamachika S; Hazama S; Izumi K; Tanigawa K
Ann Thorac Cardiovasc Surg; 2003 Feb; 9(1):22-8. PubMed ID: 12667126
[TBL] [Abstract][Full Text] [Related]
15. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
Brister SJ; Ofosu FA; Buchanan MR
Thromb Haemost; 1993 Aug; 70(2):259-62. PubMed ID: 8236131
[TBL] [Abstract][Full Text] [Related]
16. Plasmin generation and D-dimer formation during cardiopulmonary bypass.
Chandler WL; Velan T
Blood Coagul Fibrinolysis; 2004 Oct; 15(7):583-91. PubMed ID: 15389126
[TBL] [Abstract][Full Text] [Related]
17. Effect of polymer coating (poly 2-methoxyethylacrylate) of the oxygenator on hemostatic markers during cardiopulmonary bypass in children.
Eisses MJ; Geiduschek JM; Jonmarker C; Cohen GA; Chandler WL
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):28-34. PubMed ID: 17289476
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
[TBL] [Abstract][Full Text] [Related]
19. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
[TBL] [Abstract][Full Text] [Related]
20. Thrombophilic variables do not increase the generation or procoagulant activity of thrombin during cardiopulmonary bypass.
Raivio P; Petäjä J; Kuitunen A; Lassila R
Ann Thorac Surg; 2008 Feb; 85(2):536-42. PubMed ID: 18222259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
